1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Vital Signs - The Analyst's Perspective - March 2015 Issue

Vital Signs - The Analyst's Perspective - March 2015 Issue

  • April 2015
  • -
  • Frost & Sullivan
  • -
  • 7 pages

This issue of Vital Signs, released on April 3, 2015, discusses next-generation sequencing bioinformatics partnerships, FDA approval of Novartis's ZARXIO, 23andMe's foray into drug development, and Johnson & Johnson's sale of Cordis to Cardinal Health.

NGS Bioinformatics Partnerships Heat Up

Source: Cartagenia and Tute Genomics, March 17, 2015
On March 17, two announcements emerged concerning next-generation sequencing (NGS) informatics companies teaming up to provide complete workflows. DNAnexus and Tute Genomics joined forces, while Cartegenia and N-of-One will integrate their offerings as well. DNAnexus and Tute Genomics have teamed up to provide an integrated solution for upstream primary analyses and downstream interpretation along the NGS bioinformatics workflow. DNAnexus, based in Mountain View, Calif., provides a configurable cloud-based platform for storage, computing, and NGS primary and secondary data analysis. Tute Genomics, based in Provo, Utah, provides a cloud-based solution for genome annotation and clinical interpretation and reporting.

The combined offering streamlines data transfer between the two offerings so end users can easily transfer variant data from DNAnexus to Tute’s platform for downstream analysis. Cartegnia, based in Cambridge, Mass., offers its Bench Lab NGS platform, which manages NGS data, performs variant calling, and puts variants into patient-related information and phenotypic context. N-of-One provides clinical interpretation services of NGS data. The combined offering is aimed at pathology labs, allowing them to
integrate N-of-One’s genomic and tumor intreprations into their Bench Lab NGS platforms.

Table Of Contents

Vital Signs - The Analyst's Perspective - March 2015 Issue
LIFE SCIENCES
NGS Bioinformatics Partnerships Heat Up . 2
Who Wins with Recent FDA Approval of Novartis's ZARXIO Biosimilar?. 3
In Big Shift, 23andMe will Invent Drugs Using Customer Data. 4
JandJ Sells Cordis to Cardinal: A Worthy Investment?. 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets

Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Assess current market dynamics and estimate future demand for sample preparation in genomics, proteomics and epigenomics. - Gain insight into existing products as well as new developments ...

Genome Editing/Genome Engineering Market by Technology, Applications, End User - Global Forecast to 2021

Genome Editing/Genome Engineering Market by Technology, Applications, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The genome editing market is projected to reach USD 5.54 billion by 2021 from USD 2.84 billion in 2016, growing at a CAGR of 14.3% in the next five years (2016 to 2021). The genome editing market is undergoing ...

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Inborn Gene or Chromosome Alterations - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Inborn Gene or Chromosome Alterations - Medical Devices Pipeline ...

Global Precision Medicine Market

December 2016 $ 4250

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.